Contact
searchSearch
HMP Global

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Chronic Lymphocytic Leukemia Topic Center

Featured Article

News
Exploring the Cost-Effectiveness of Acalabrutinib Regimens for Treatment-Naive CLL
07/31/2023
Julie Gould
Acalabrutinib monotherapy may be a cost-effective treatment option for Medicare patients with treatment-naïve chronic lymphocytic leukemia, according to recent findings.
Acalabrutinib monotherapy may be a cost-effective treatment option for Medicare patients with treatment-naïve chronic lymphocytic leukemia, according to recent findings.
Acalabrutinib monotherapy may be...
07/31/2023
First Report Managed Care
News
Adding Anti-CD20 Monoclonal Antibody to BTKi Therapy Superior to BTKi Alone in Patients With CLL
07/14/2023
Jolynn Tumolo
New research indicates that adding an anti-CD20 monoclonal antibody to a BTK inhibitor in patients with untreated or relapsed/refractory CLL could provide significantly superior efficacy with an equally safe profile.
New research indicates that adding an anti-CD20 monoclonal antibody to a BTK inhibitor in patients with untreated or relapsed/refractory CLL could provide significantly superior efficacy with an equally safe profile.
New research indicates that...
07/14/2023
First Report Managed Care
News
Most Patients With Relapsed/Refractory CLL Respond to Obinutuzumab Combination Therapy
06/23/2023
Jolynn Tumolo
Researchers studied the efficacy and tolerability of obinutuzumab plus bendamustine in patients with relapsed/refractory chronic lymphocytic leukemia.
Researchers studied the efficacy and tolerability of obinutuzumab plus bendamustine in patients with relapsed/refractory chronic lymphocytic leukemia.
Researchers studied the efficacy...
06/23/2023
First Report Managed Care
News
Ceralasertib Alone Shows Little Benefit for Relapsed/Refractory CLL
06/22/2023
Jolynn Tumolo
For the study, patients who were heavily pretreated for chronic lymphocytic leukemia received ceralasertib with vs without acalabrutinib.
For the study, patients who were heavily pretreated for chronic lymphocytic leukemia received ceralasertib with vs without acalabrutinib.
For the study, patients who were...
06/22/2023
First Report Managed Care
Headshot of Clement Chung, Houston Methodist, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Considerations for Selecting Small Molecule Inhibitors for Patients With CLL
05/26/2023
Maria Asimopoulos
Clement Chung, PharmD, MS, BCOP, BCPS, senior clinical pharmacy specialist, hematology and oncology, Houston Methodist West Hospital, reviews the landscape of small molecule inhibitors for chronic lymphocytic leukemia, including important...
Clement Chung, PharmD, MS, BCOP, BCPS, senior clinical pharmacy specialist, hematology and oncology, Houston Methodist West Hospital, reviews the landscape of small molecule inhibitors for chronic lymphocytic leukemia, including important...
Clement Chung, PharmD, MS, BCOP,...
05/26/2023
First Report Managed Care
News
Treatment Discontinuation Patterns Highlight Need for Tolerable CLL Therapies
05/23/2023
Jolynn Tumolo
The real-world study involved patients with chronic lymphocytic leukemia who received a variety of therapies in first- and second-line settings.
The real-world study involved patients with chronic lymphocytic leukemia who received a variety of therapies in first- and second-line settings.
The real-world study involved...
05/23/2023
First Report Managed Care
News
Survival Disparity Persists Between Black and White Patients With CLL
05/19/2023
Jolynn Tumolo
When compared to White patients, Black patients with chronic lymphocytic leukemia face a persistent survival disadvantage that is not found among other racial minority groups, researchers reported.
When compared to White patients, Black patients with chronic lymphocytic leukemia face a persistent survival disadvantage that is not found among other racial minority groups, researchers reported.
When compared to White patients,...
05/19/2023
First Report Managed Care
News
Fewer Black Patients Prescribed Novel Agents for CLL in the VA System
04/24/2023
Jolynn Tumolo
“Further studies should explore other socioeconomic and cultural factors that may drive these racial disparities, as well as the safety and effectiveness of treatments by race, to better understand how racial disparities might impact patient...
“Further studies should explore other socioeconomic and cultural factors that may drive these racial disparities, as well as the safety and effectiveness of treatments by race, to better understand how racial disparities might impact patient...
“Further studies should explore...
04/24/2023
First Report Managed Care
News
BTK Inhibitor Regimens: Comparing Outcomes in Real-World Patients With R/R CLL
04/19/2023
Jolynn Tumolo
Researchers studied survival outcomes in patients who were treated with either ibrutinib or idelasib plus rituximab after receiving 2 previous lines of therapy.
Researchers studied survival outcomes in patients who were treated with either ibrutinib or idelasib plus rituximab after receiving 2 previous lines of therapy.
Researchers studied survival...
04/19/2023
First Report Managed Care
News
Additional Malignancies Reduce Survival in Patients With Chronic Lymphocytic Leukemia
03/27/2023
Jolynn Tumolo
“In cases with a diagnosis of CLL, care should be taken to detect other malignancies,” researchers wrote, “and it should be kept in mind that the presence of other malignancies may reduce survival.”
“In cases with a diagnosis of CLL, care should be taken to detect other malignancies,” researchers wrote, “and it should be kept in mind that the presence of other malignancies may reduce survival.”
“In cases with a diagnosis of...
03/27/2023
First Report Managed Care
News
Real-World Evidence Reveals Patient Outcomes With Ibrutinib Treatment for CLL
03/03/2023
Maria Asimopoulos
In light of real-world data, researchers studied outcomes and prognoses in patients with chronic lymphocytic leukemia who received ibrutinib monotherapy.
In light of real-world data, researchers studied outcomes and prognoses in patients with chronic lymphocytic leukemia who received ibrutinib monotherapy.
In light of real-world data,...
03/03/2023
First Report Managed Care

Newsfeed

News
Exploring the Cost-Effectiveness of Acalabrutinib Regimens for Treatment-Naive CLL
07/31/2023
Julie Gould
Acalabrutinib monotherapy may be a cost-effective treatment option for Medicare patients with treatment-naïve chronic lymphocytic leukemia, according to recent findings.
Acalabrutinib monotherapy may be a cost-effective treatment option for Medicare patients with treatment-naïve chronic lymphocytic leukemia, according to recent findings.
Acalabrutinib monotherapy may be...
07/31/2023
First Report Managed Care
News
Adding Anti-CD20 Monoclonal Antibody to BTKi Therapy Superior to BTKi Alone in Patients With CLL
07/14/2023
Jolynn Tumolo
New research indicates that adding an anti-CD20 monoclonal antibody to a BTK inhibitor in patients with untreated or relapsed/refractory CLL could provide significantly superior efficacy with an equally safe profile.
New research indicates that adding an anti-CD20 monoclonal antibody to a BTK inhibitor in patients with untreated or relapsed/refractory CLL could provide significantly superior efficacy with an equally safe profile.
New research indicates that...
07/14/2023
First Report Managed Care
News
Most Patients With Relapsed/Refractory CLL Respond to Obinutuzumab Combination Therapy
06/23/2023
Jolynn Tumolo
Researchers studied the efficacy and tolerability of obinutuzumab plus bendamustine in patients with relapsed/refractory chronic lymphocytic leukemia.
Researchers studied the efficacy and tolerability of obinutuzumab plus bendamustine in patients with relapsed/refractory chronic lymphocytic leukemia.
Researchers studied the efficacy...
06/23/2023
First Report Managed Care
News
Ceralasertib Alone Shows Little Benefit for Relapsed/Refractory CLL
06/22/2023
Jolynn Tumolo
For the study, patients who were heavily pretreated for chronic lymphocytic leukemia received ceralasertib with vs without acalabrutinib.
For the study, patients who were heavily pretreated for chronic lymphocytic leukemia received ceralasertib with vs without acalabrutinib.
For the study, patients who were...
06/22/2023
First Report Managed Care
News
Treatment Discontinuation Patterns Highlight Need for Tolerable CLL Therapies
05/23/2023
Jolynn Tumolo
The real-world study involved patients with chronic lymphocytic leukemia who received a variety of therapies in first- and second-line settings.
The real-world study involved patients with chronic lymphocytic leukemia who received a variety of therapies in first- and second-line settings.
The real-world study involved...
05/23/2023
First Report Managed Care
News
Survival Disparity Persists Between Black and White Patients With CLL
05/19/2023
Jolynn Tumolo
When compared to White patients, Black patients with chronic lymphocytic leukemia face a persistent survival disadvantage that is not found among other racial minority groups, researchers reported.
When compared to White patients, Black patients with chronic lymphocytic leukemia face a persistent survival disadvantage that is not found among other racial minority groups, researchers reported.
When compared to White patients,...
05/19/2023
First Report Managed Care
News
Fewer Black Patients Prescribed Novel Agents for CLL in the VA System
04/24/2023
Jolynn Tumolo
“Further studies should explore other socioeconomic and cultural factors that may drive these racial disparities, as well as the safety and effectiveness of treatments by race, to better understand how racial disparities might impact patient...
“Further studies should explore other socioeconomic and cultural factors that may drive these racial disparities, as well as the safety and effectiveness of treatments by race, to better understand how racial disparities might impact patient...
“Further studies should explore...
04/24/2023
First Report Managed Care
News
BTK Inhibitor Regimens: Comparing Outcomes in Real-World Patients With R/R CLL
04/19/2023
Jolynn Tumolo
Researchers studied survival outcomes in patients who were treated with either ibrutinib or idelasib plus rituximab after receiving 2 previous lines of therapy.
Researchers studied survival outcomes in patients who were treated with either ibrutinib or idelasib plus rituximab after receiving 2 previous lines of therapy.
Researchers studied survival...
04/19/2023
First Report Managed Care
News
Additional Malignancies Reduce Survival in Patients With Chronic Lymphocytic Leukemia
03/27/2023
Jolynn Tumolo
“In cases with a diagnosis of CLL, care should be taken to detect other malignancies,” researchers wrote, “and it should be kept in mind that the presence of other malignancies may reduce survival.”
“In cases with a diagnosis of CLL, care should be taken to detect other malignancies,” researchers wrote, “and it should be kept in mind that the presence of other malignancies may reduce survival.”
“In cases with a diagnosis of...
03/27/2023
First Report Managed Care
News
Real-World Evidence Reveals Patient Outcomes With Ibrutinib Treatment for CLL
03/03/2023
Maria Asimopoulos
In light of real-world data, researchers studied outcomes and prognoses in patients with chronic lymphocytic leukemia who received ibrutinib monotherapy.
In light of real-world data, researchers studied outcomes and prognoses in patients with chronic lymphocytic leukemia who received ibrutinib monotherapy.
In light of real-world data,...
03/03/2023
First Report Managed Care
News
AI Tool for Drug Repurposing May Offer New Hope for Treating Rare and Neglected Diseases
09/27/2024
Harvard Medical School researchers unveil a potentially groundbreaking AI tool, TxGNN, that identifies potential drug candidates for 17 080 diseases, offering hope for patients with rare and neglected conditions.
Harvard Medical School researchers unveil a potentially groundbreaking AI tool, TxGNN, that identifies potential drug candidates for 17 080 diseases, offering hope for patients with rare and neglected conditions.
Harvard Medical School...
09/27/2024
First Report Managed Care
News
Impact of Multi-Drug Resistant Bacterial Infections on Patients With Bronchiectasis
09/27/2024
A study published in the Annals of Clinical Microbiology and Antimicrobials explores the impact of multidrug-resistant (MDR) bacterial infections on the clinical outcomes of adult patients with bronchiectasis, finding a significant increase...
A study published in the Annals of Clinical Microbiology and Antimicrobials explores the impact of multidrug-resistant (MDR) bacterial infections on the clinical outcomes of adult patients with bronchiectasis, finding a significant increase...
A study published in the Annals...
09/27/2024
First Report Managed Care
News
Understanding the Pharmacology and Clinical Application of siRNA Therapies
09/25/2024
Explore the state of siRNA-based therapies, relevant pharmacology insights, and care strategies aimed to enhance patient outcomes.
Explore the state of siRNA-based therapies, relevant pharmacology insights, and care strategies aimed to enhance patient outcomes.
Explore the state of siRNA-based...
09/25/2024
First Report Managed Care
News
Impact of Long-Term Acute Care Hospital Closures on Patient Care Patterns and Outcomes
09/23/2024
A study published in JAMA Network Open examines the impact of long-term acute care hospital closures on care patterns and outcomes for patients requiring mechanical ventilation, revealing changes in discharge patterns and advanced directive...
A study published in JAMA Network Open examines the impact of long-term acute care hospital closures on care patterns and outcomes for patients requiring mechanical ventilation, revealing changes in discharge patterns and advanced directive...
A study published in JAMA...
09/23/2024
First Report Managed Care
News
Treatment Combination Advances Metastatic Urothelial Cancer Care
09/23/2024
Recent data has established enfortumab vedotin (EV) and pembrolizumab (P) as the preferred first-line (1L) treatment option for patients with metastatic urothelial cancer, according to an article in American Society of Clinical Oncology...
Recent data has established enfortumab vedotin (EV) and pembrolizumab (P) as the preferred first-line (1L) treatment option for patients with metastatic urothelial cancer, according to an article in American Society of Clinical Oncology...
Recent data has established...
09/23/2024
First Report Managed Care
News
Investigational 4F-PCC Non-Inferior to Control for Vitamin K Antagonist Reversal
09/23/2024
An investigational 4-factor prothrombin complex concentrate (4F-PCC) was hemostatically non-inferior to a licensed control 4F-PCC for the rapid reversal of vitamin K antagonists (VKA) in patients needing urgent surgery, according to study...
An investigational 4-factor prothrombin complex concentrate (4F-PCC) was hemostatically non-inferior to a licensed control 4F-PCC for the rapid reversal of vitamin K antagonists (VKA) in patients needing urgent surgery, according to study...
An investigational 4-factor...
09/23/2024
First Report Managed Care
News
Exploring the Mechanisms of FDA-Approved siRNA Treatments in Disease Therapy
09/20/2024
Explore the groundbreaking advancements in RNA interference (RNAi) therapeutics, with a focus on the 6 US Food and Drug Administration (FDA)-approved small interfering RNA (siRNA) treatments and how they are revolutionizing disease treatment...
Explore the groundbreaking advancements in RNA interference (RNAi) therapeutics, with a focus on the 6 US Food and Drug Administration (FDA)-approved small interfering RNA (siRNA) treatments and how they are revolutionizing disease treatment...
Explore the groundbreaking...
09/20/2024
First Report Managed Care
News
High Mortality and Impairment Rates Among Older Adults in Long-Term Acute Care Hospitals
09/20/2024
Long-term acute care hospitals (LTCHs) provide critical, multidisciplinary care for medically complex patients, but survival rates and long-term functional outcomes remain poor, according to a study published in JAMA Network Open.
Long-term acute care hospitals (LTCHs) provide critical, multidisciplinary care for medically complex patients, but survival rates and long-term functional outcomes remain poor, according to a study published in JAMA Network Open.
Long-term acute care hospitals...
09/20/2024
First Report Managed Care
News
Addressing Stigma is Essential for Increasing PrEP Uptake and Adherence in HIV Prevention Efforts
09/20/2024
Addressing stigma associated with pre-exposure prophylaxis (PrEP) is crucial for improving its uptake and adherence among eligible populations, according to study results published in Sexes.
Addressing stigma associated with pre-exposure prophylaxis (PrEP) is crucial for improving its uptake and adherence among eligible populations, according to study results published in Sexes.
Addressing stigma associated...
09/20/2024
First Report Managed Care
News
UC Davis Health Unveils Innovative Strategy to Shield Patients With COPD and Asthma From Wildfire Hazards
09/20/2024
As wildfires become an annual threat due to climate change, health systems must proactively adopt air quality-focused population health approaches to protect vulnerable patients with chronic respiratory conditions like COPD and asthma,...
As wildfires become an annual threat due to climate change, health systems must proactively adopt air quality-focused population health approaches to protect vulnerable patients with chronic respiratory conditions like COPD and asthma,...
As wildfires become an annual...
09/20/2024
First Report Managed Care

Advertisement

Advertisement

FRMC Volume 21, Issue 3

Current Issue

September 2024
Volume 21
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement